Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share details the company has an Investigational New Drug request with the U.S. FDA for its investigation of using psychedelic compound DMT, for the treatment of stroke-related dysfunction. Moreau telling Proactive the company is looking for direction as Algernon has filed new provisional patents for new forms of DMT, in addition to the formulation, dosage and method of use claims for ischemic stroke.
Algernon files pre-IND with FDA for direction regarding the use of DMT in stroke patients
